| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.091 | 0.008 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.009 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.095 | 0.01 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.082 | 0.01 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.079 | 0.01 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.079 | 0.01 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | -0.081 | 0.01 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | 0.072 | 0.01 |
| mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.01 |